# To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

> **NCT05651191** · EARLY_PHASE1 · UNKNOWN · sponsor: **Hrain Biotechnology Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Human CD19 Targeted DASH CAR-T Cells Injection

## Key facts

- **NCT ID:** NCT05651191
- **Lead sponsor:** Hrain Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-21
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2022-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05651191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05651191, "To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05651191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*